about
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesisTetraspanin CD37 directly mediates transduction of survival and apoptotic signalsEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyMethylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemiaEpigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemiaCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaTargeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalAccurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform.Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibPretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemiaPentostatin in steroid-refractory acute graft-versus-host diseasePhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneThe novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoDaunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia ModelGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaTargeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemiaPrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data.Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Rituximab in chronic lymphocytic leukemia.Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphomaIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLA phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
P50
Q24318614-703E9047-FA66-4A16-B70F-388A8E4459C0Q24336378-8B935E2D-804E-44FC-9ABC-BE77F04D08B4Q24563021-A885DE99-D14C-417E-857E-75BE63520814Q24619893-1507B9D1-1AA8-40E0-957E-D5818557CE55Q24652017-740BBD8B-2029-4A25-BB8A-47F3D95FF324Q24681296-65365F6C-0FF4-4600-8A32-1C10F742F2A4Q24681992-5488B3E2-2AEF-4B4A-AAF2-DF18586C941AQ25257477-6C1B8B48-AA62-46B9-961F-FD4F75D9CE35Q27304652-FEE37658-DEB9-4818-880F-003A9D6DD2E9Q27674083-D620FF3E-2F28-4EDB-852A-8107A4E2D9C2Q27824806-7D742745-5CA1-456F-8CF8-0F12516EF875Q27853011-827EB145-C620-4EF4-963C-0D16A44A642EQ28209814-F5D5615C-A1EE-478C-9BF2-6A70702DD79EQ28243489-00B749CB-E16C-45BE-A03F-CF922F00A41EQ28245825-764385D2-17DD-4A30-8722-75AFFD983B76Q28261949-6551A1F9-6559-4BB0-A4B2-7C9393A27CC6Q28475976-CA01814A-FFC8-40A8-805B-A6777AE832EBQ28553703-AFF91EB2-BB1B-4DCB-98AC-271A244F92A4Q28751751-94FC9976-3465-492D-8E79-B4439452AE24Q28833494-87EDBE7C-B079-4F16-86A6-08527551A47AQ30449092-7459B7E3-75F0-4D4B-B4CB-4B7452DC51D2Q30535265-D722832A-195D-4AA6-8137-780C985E6BDBQ30577607-7E3B0661-1874-4628-8598-17A9AE6B7E61Q30622245-E11C3E7E-AE59-43A0-B039-86AE93E079AFQ30846971-CA405760-8F24-4DD1-B787-C3BDCD36D86FQ33272682-FD707B35-D379-4CDB-B50C-5230F432A2E8Q33342242-6966969F-7D29-409D-A156-D1D1144953A9Q33366496-29C5ECB1-9C9D-40DE-B975-0B6E235F148AQ33366608-7FCDBC9D-786D-48F9-9426-684FDC538216Q33371900-FAA5C2E3-A943-4625-9BF0-1D316F3E6EB0Q33383571-B1489DD2-23DC-4C7D-B25F-18A5A46C05BDQ33386193-677435F8-8E3A-4BA5-A197-025C0ED98E6EQ33388976-6C4C89E5-FB72-4637-B49D-4825298D9134Q33389485-5DED895F-A359-4857-9C36-71A374AF2D25Q33400351-ADD48A04-7271-4D90-9DC4-70B296B0161CQ33412064-3895BAED-7B54-4012-BE85-E0D1810E41B9Q33413834-AE8AED97-4B63-42F4-B2A7-FCC79D4843AEQ33417223-395A7262-560D-46E2-A044-9E3F4F9326A6Q33418091-C3F2330B-34C2-44D6-A4DD-521B16515A39Q33418456-E3EE42A0-96E2-45DA-9BC7-2844C387B1C1
P50
name
John C Byrd
@ast
John C Byrd
@en
John C Byrd
@es
John C Byrd
@nl
type
label
John C Byrd
@ast
John C Byrd
@en
John C Byrd
@es
John C Byrd
@nl
prefLabel
John C Byrd
@ast
John C Byrd
@en
John C Byrd
@es
John C Byrd
@nl
P950
P214
3146573803038101136
P31
P735
P7859
lccn-no2017047187